Related references
Note: Only part of the references are listed.A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
B. Glimelius et al.
ANNALS OF ONCOLOGY (2008)
Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer
L. F. de Geus-Oei et al.
ANNALS OF ONCOLOGY (2008)
The expanding role of PET technology in the management of patients with colorectal cancer
R. A. Herbertson et al.
ANNALS OF ONCOLOGY (2007)
Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer:: A proposal for standardization of patient characteristic reporting and stratification
H. Sorbye et al.
ANNALS OF ONCOLOGY (2007)
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer
S. M. Eschmann et al.
LUNG CANCER (2007)
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment
HA Wieder et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use
WA Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer:: results of a multivariate analysis of 3825 patients
CH Köhne et al.
ANNALS OF ONCOLOGY (2002)
Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study
TJM Ruers et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
